Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin

W D Shields1, R Sankar

  • 1Departments of Pediatrics and Neurology, UCLA School of Medicine 90095-1752, USA.

Seminars in Pediatric Neurology
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Vigabatrin, an anti-seizure medication, effectively treats infantile spasms and other seizure types in children by increasing brain GABA levels. While not yet FDA-approved, it offers a promising new epilepsy treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving the efficiency of induction motor drive by flux and torque control: A hybrid LSE-RERNN approach.

ISA transactions·2024
Same author

Benthic foraminifera as an environmental proxy for pollutants along the coast of Chennai, India.

Chemosphere·2022
Same author

Large magnetoresistance and quantum oscillations in Sn<sub>0.05</sub>Pb<sub>0.95</sub>Te.

Journal of physics. Condensed matter : an Institute of Physics journal·2021
Same author

Contrasting the Surface Phonon Dispersion of Pb_{0.7}Sn_{0.3}Se in Its Topologically Trivial and Nontrivial Phases.

Physical review letters·2019
Same author

Gd<sub>2</sub>Te<sub>3</sub>: an antiferromagnetic semimetal.

Journal of physics. Condensed matter : an Institute of Physics journal·2019
Same author

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis.

The Journal of laryngology and otology·2018
Same journal

Concussion in contact sport: risks, detection, & prevention.

Seminars in pediatric neurology·2026
Same journal

A multidisciplinary, symptom-targeted approach to rehabilitation in pediatric concussion.

Seminars in pediatric neurology·2026
Same journal

Pediatric concussion beyond sports: Falls, play, and everyday activities.

Seminars in pediatric neurology·2026
Same journal

Return-to-school protocols in pediatric concussion care.

Seminars in pediatric neurology·2026
Same journal

Improving concussion recognition in youth sports: the role of parents, coaches, and community education.

Seminars in pediatric neurology·2026
Same journal

Concussion management, rehabilitation, and societal impact.

Seminars in pediatric neurology·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pediatric Neurology

Background:

  • Vigabatrin is a structural analogue of gamma-aminobutyric acid (GABA).
  • It functions by irreversibly inhibiting GABA-transaminase, leading to elevated brain GABA concentrations.
  • This mechanism is crucial for understanding its therapeutic effects in epilepsy.

Purpose of the Study:

  • To evaluate the efficacy of vigabatrin in the medical management of pediatric epilepsy.
  • To identify specific seizure types that respond favorably to vigabatrin treatment.
  • To assess the safety and potential limitations of vigabatrin in children.

Main Methods:

  • Pharmacological analysis of vigabatrin's mechanism of action.
  • Clinical review of vigabatrin's effectiveness across various pediatric seizure syndromes.

Related Experiment Videos

  • Comparative analysis of vigabatrin's efficacy against existing epilepsy treatments.

    • Main Results:

    • Vigabatrin demonstrates significant effectiveness in treating infantile spasms, particularly those associated with tuberous sclerosis.
    • The drug is also beneficial for partial seizures and certain generalized seizures, including Lennox-Gastaut syndrome.
    • A notable adverse effect is the potential exacerbation of myoclonic seizures.

    Conclusions:

    • Vigabatrin represents a significant advancement in pediatric epilepsy management.
    • Its targeted efficacy for specific seizure types, like infantile spasms, makes it a valuable therapeutic option.
    • While awaiting US FDA approval, its international availability and expected release suggest a growing role in epilepsy treatment.